Discover how to adopt the optimal models for your immuno-oncology (IO) drug evaluation, and understand when to use them and why, in our upcoming webinar.
Leveraging patient-derived model systems allows you to better understand therapeutic efficacy and to identify responsive patient populations, which enables you to enhance your translational success and advance your studies more efficiently.
In this webinar, we will provide an insight into patient-derived model systems including in vivo, in vitro and ex vivo platforms along with a panel Q&A to gain deeper understanding from our experts.
Rajendra Kumari, PhD, Global Head of Scientific Communications, Crown Bioscience
After receiving her PhD from the University of Leicester in Molecular Pharmacology, Rajendra joined the Division of pre-clinical Oncology, School of Clinical Sciences, University of Nottingham as a postdoctoral fellow, building expertise in cancer cell biology, model development, in vitro, in vivo, imaging capabilities and molecular pharmacology. In 2005, Rajendra took the role of Project & Business Manager of the Preclinical Oncology Services (PRECOS) contract research business unit and lecturer/assistant professor in 2008. Rajendra was pivotal in the commercialisation of the unit and eventual spinout of PRECOS Ltd in 2010, acting as Chief Operations Officer, Board Director and co-founder. Following the merger with Crown Bioscience in 2013, Rajendra led Crown Bioscience’s European site as CSO & General Manager. In 2018, Rajendra became Global Head of Scientific Communications for all platforms at the company. Rajendra is a member of the American Association of Cancer Research and British Association of Cancer Research and has authored over 40 abstracts and publications.
Gera Goverse, PhD, Director Immuno-Oncology, Crown Bioscience
Dr. Gera Goverse joined OcellO in 2017 and is Director of Immuno-Oncology at Crown Bioscience Netherlands. Her expertise is in assay development for testing drug candidates targeting the immune cell response leading to the killing of tumors in 3D high content image assays.
Dr. Goverse who obtained her PhD in Immunology at the VU Medical Centre Amsterdam and continued her post-doctoral studies at the KU Leuven, applies her obtained knowledge within these complex assays studying different subsets of immune cells and is specialized in the role of the myeloid cell compartment.
Gerold Feuer, PhD, Senior Director, Scientific Research & Innovation, Crown Bioscience
Dr. Gerold Feuer was Founder and Chief Scientific Officer of HuMurine Technologies, Inc. Dr. Feuer obtained his B.A. at U.C. Berkeley and his PhD at U.C. Irvine. After post-doctoral studies at UCLA Medical Center on human retrovirus (HTLV-1 and HIV-1) infections in humanized mice, Dr. Feuer spent 18 years as a professor in the Department of Microbiology and Immunology at SUNY Upstate MedicalUniversity, Syracuse, where he established and served as the Director of SUNY UMU’s Center for Humanized SCID Mouse Models. HuMurine was founded in 2008 as a SUNY- academic spinoff company and was the first company to commercialize the humanized immune system mouse. HuMurine laboratory operations relocated to adjacent to the U.C. Davis Medical Center and Institute for Regenerative Cures in Sacramento, CA, in 2011. Dr. Feuer retired from SUNY UMU in 2015 to return to California and to run HuMurine full-time. Dr. Feuer has extensive background in the fields of human virology, immuno-oncology, gene therapies and human hematopoietic stem cells.